New cocktail of drugs shows promise for stomach cancer patients
NCT ID NCT07655661
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of four drugs—mannatide, two chemotherapy drugs, and an immunotherapy—as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has spread or come back. The study will enroll 52 participants to see if the combo shrinks tumors and controls the disease. Researchers will also monitor side effects and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mannatide, oxaliplatin, capecitabine, tislelizumab
What this could lead to
If it works, this could offer a new first-line treatment option for people with advanced stomach cancer, potentially shrinking tumors and extending life.
What could go wrong
This is an early phase 2 trial with only 52 people, no comparison group, and it hasn't started yet. The combination may cause significant side effects and may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••